Role of insulin resistance in Alzheimer’s disease

Metabolic Brain Disease

Volumn 30, Issue 4, 2015, Pages 839-851

  Cai, Zhiyou ^a   Xiao, Ming ^b   Chang, Liying ^c   Yan, Liang Jun ^d  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c HUBEI UNIVERSITY OF ARTS AND SCIENCE   (China)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Alzheimer s disease; A ; Cognitive impairment; Insulin resistance; Tau hyperphosphorylation

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; BETA SECRETASE; GAMMA SECRETASE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; COGNITIVE DEFECT; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; BRAIN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; HUMANS; INSULIN RESISTANCE; NEUROFIBRILLARY TANGLES; OXIDATIVE STRESS; TAU PROTEINS;

EID: 84943363460     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9631-3     Document Type: Review

References (183)

1. Araki A (2010) Dementia and insulin resistance in patients with diabetes mellitus. Nihon Rinsho 68: 569-574.
2. Babic T (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 67: 558.
3. Barron AM, Rosario ER, Elteriefi R, Pike CJ (2013) Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer's disease. PLoS ONE 8: e78554.
4. Barrou Z, Lemaire A, Boddaert J, Verny M (2008) Diabetes mellitus and cognition: is there a link? Psychol Neuropsychiatr Vieil 6: 189-198.
5. Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA (2008) Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model. J Alzheimers Dis 15: 625-640.
6. Bhat NR, Thirumangalakudi L (2013) Increased tau phosphorylation and impaired brain insulin/igf signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis 36: 781-789.
7. Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89: 1313-1317.
8. Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33: 1041-1044.
9. Bikhazi AB, Azar ST, Birbari AE, El-Zein GN, Haddad GE, Haddad RE, Bitar KM (2000) Characterization of insulin-resistance: role of receptor alteration in insulin-dependent diabetes mellitus, essential hypertension and cardiac hypertrophy. Eur J Pharm Sci 11: 299-306.
10. Birse RT, Soderberg JA, Luo J, Winther AM, Nassel DR (2011) Regulation of insulin-producing cells in the adult Drosophila brain via the tachykinin peptide receptor DTKR. J Exp Biol 214: 4201-4208.
11. Blum D, Buee L (2013) Alzheimer's disease risk, obesity and tau: is insulin resistance guilty? Expert Rev Neurother 13: 461-463.
12. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 122: 1339-1353.
13. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15: 1807-1821.
14. Briyal S, Shepard C, Gulati A (2014) Endothelin receptor type B agonist, IRL-1620, prevents beta amyloid (Abeta) induced oxidative stress and cognitive impairment in normal and diabetic rats. Pharmacol Biochem Behav 120: 65-72.
15. Cai Z, Zhao B, Ratka A (2011) Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neuromol Med 13: 223-250.
16. Cai Z, Zhao Y, Zhao B (2012) Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr Alzheimers Res 9: 864-879.
17. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490: 127-133.
18. Chen Z, Zhong C (2013) Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108: 21-43.
19. Cho DH, Lee EJ, Kwon KJ, Shin CY, Song KH, Park JH, Jo I, Han SH (2013) Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem 126: 685-695.
20. CiobicaA, Padurariu M, BildW, Stefanescu C (2011) Cardiovascular risk factors as potential markers for mild cognitive impairment and Alzheimer's disease. Psychiatr Danub 23: 340-346.
21. Cole AR, SoutarMP, Rembutsu M, van Aalten L, Hastie CJ, McLauchlan H, Peggie M, Balastik M, Lu KP, Sutherland C (2008) Relative resistance of Cdk5-phosphorylated CRMP2 to dephosphorylation. J Biol Chem 283: 18227-18237.
22. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20: 558-567.
23. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI (2012) Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res 1441: 64-78.
24. Craft S (2005) Insulin resistance syndrome and Alzheimer's disease: ageand obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26(Suppl 1): 65-69.
25. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, ArbuckleM, CallaghanM, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69: 29-38.
26. de la Monte SM (2012a) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimers Res 9: 35-66.
27. de la Monte SM (2012b) Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72: 49-66.
28. De La Monte SM (2012c) Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulinresistance diseases. Panminerva Med 54: 171-178.
29. de laMonte SM (2012d) Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) 4: 1582-1605.
30. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2: 1101-1113.
31. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10: 89-109.
32. de la Monte SM, Re E, Longato L, Tong M (2012) Dysfunctional proceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. J Alzheimers Dis 30(Suppl 2): S217-S229.
33. de la Torre JC (2010) Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev 9: 218-225.
34. Deedwania P (2011) Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens (Greenwich) 13: 52-59.
35. Dhamoon MS, Noble JM, Craft S (2009) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 72: 292-293, author reply 293-294.
36. Du J, Zhang L, Liu S, Zhang C, Huang X, Li J, Zhao N, Wang Z (2009) PPARgamma transcriptionally regulates the expression of insulindegrading enzyme in primary neurons. Biochem Biophys Res Commun 383: 485-490.
37. Du LL, Xie JZ, Cheng XS, Li XH, Kong FL, Jiang X, Ma ZW, Wang JZ, Chen C, ZhouXW (2014) Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr) 36: 613-623.
38. Emmanuel Y, Cochlin LE, Tyler DJ, de Jager CA, David Smith A, Clarke K (2013) Human hippocampal energy metabolism is impaired during cognitive activity in a lipid infusion model of insulin resistance. Brain Behav 3: 134-144.
39. Erol A (2009) Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 17: 267-276.
40. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A, Del Rio J, Frechilla D (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35: 1593-1604.
41. Fava A, PlastinoM, CristianoD, Spano A, Cristofaro S, Opipari C, Chilla A, Casalinuovo F, Colica C, De Bartolo M, Pirritano D, Bosco D (2013) Insulin resistance possible risk factor for cognitive impairment in fibromialgic patients. Metab Brain Dis 28: 619-627.
42. Fowler SW, Chiang AC, Savjani RR, Larson ME, ShermanMA, Schuler DR, Cirrito JR, Lesne SE, Jankowsky JL (2014) Geneticmodulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci 34: 7871-7885.
43. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147.
44. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, Bruning JC, Schubert M (2005) Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54: 3343-3348.
45. Gasparini L, Netzer WJ, Greengard P, Xu H (2002) Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 23: 288-293.
46. Ghareeb DA, Hafez HS, Hussien HM, Kabapy NF (2011) Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction. Metab Brain Dis 26: 253-267.
47. Ghosh AK, Brindisi M, Tang J (2012) Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 120(Suppl 1): 71-83.
48. Ginsberg SD, Che S, Counts SE, Mufson EJ (2006) Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Neurochem 96: 1401-1408.
49. GreenoughMA, Camakaris J, Bush AI (2013)Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 62: 540-555.
50. Grossman H (2003) Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 8: 815-823.
51. Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60: 910-920.
52. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31: 357-367.
53. Hanyu H, Sato T (2010) Alzheimer's disease. Nihon Rinsho 68: 330-334.
54. Hawkes C, Jhamandas JH, Kar S (2005) Selective loss of basal forebrain cholinergic neurons by 192 IgG-saporin is associated with decreased phosphorylation of Ser glycogen synthase kinase-3beta. J Neurochem 95: 263-272.
55. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, Klockgether T (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokineinduced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 100: 156-168.
56. Herholz K (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35(Suppl 1): S25-S29.
57. Hildreth KL, Van Pelt RE, Schwartz RS (2012) Obesity, insulin resistance, and Alzheimer's disease. Obesity (Silver Spring) 20: 1549-1557.
58. Hiltunen M, Khandelwal VK, Yaluri N, Tiilikainen T, Tusa M, Koivisto H, KrzischM, Vepsalainen S, Makinen P, Kemppainen S, Miettinen P, Haapasalo A, Soininen H, Laakso M, Tanila H (2012) Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J Cell Mol Med 16: 1206-1222.
59. Ho L, QinW, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, CambareriG, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904.
60. Holscher C (2011) Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 39: 891-897.
61. Hsu CY, Huang CC, ChanWL, Huang PH, Chiang CH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB (2013) Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population-a nationwide cohort study. Circ J 77: 405-410.
62. Hu SH, Jiang T, Yang SS, Yang Y (2013) Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. Exp Clin Endocrinol Diabetes 121: 220-224.
63. Huang HC, Klein PS (2006)Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr Drug Targets 7: 1389-1397.
64. Irvine EE, Drinkwater L, Radwanska K, Al-Qassab H, Smith MA, O'Brien M, Kielar C, Choudhury AI, Krauss S, Cooper JD, Withers DJ, Giese KP (2011) Insulin receptor substrate 2 is a negative regulator of memory formation. Learn Mem 18: 375-383.
65. Izco M, Martinez P, Corrales A, Fandos N, Garcia S, Insua D, Montanes M, Perez-Grijalba V, Rueda N, Vidal V, Martinez-Cue C, Pesini P, Sarasa M (2014) Changes in the brain and plasma Abeta peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuroscience 263: 269-279.
66. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, Sayers AR, Brown DA, Fraser JR (2000) Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 26: 41-54.
67. Jiang Q, Heneka M, Landreth GE (2008) The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22: 1-14.
68. Jimenez-Palomares M, Ramos-Rodriguez JJ, Lopez-Acosta JF, Pacheco-Herrero M, Lechuga-Sancho AM, Perdomo G, Garcia-Alloza M, Cozar-Castellano I (2012) Increased Abeta production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 302: E1373-E1380.
69. Jo DG, Arumugam TV, Woo HN, Park JS, Tang SC, Mughal M, Hyun DH, Park JH, Choi YH, Gwon AR, Camandola S, Cheng A, Cai H, Song W, Markesbery WR, Mattson MP (2010) Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiol Aging 31: 917-925.
70. Jovanovic Z (2012) Mechanisms of neurodegeneration in Alzheimer's disease. Med Pregl 65: 301-307.
71. Kalinin S, Richardson JC, Feinstein DL (2009) A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimers Res 6: 431-437.
72. Kaundal RK, Sharma SS (2010) Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect 23: 241-256.
73. Kawamori R (1996) Insulin resistance seen in non-insulin dependent diabetes mellitus and hypertension. Hypertens Res 19(Suppl 1): S61-S64.
74. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS ONE 4: e7917.
75. Khoo CL (2007) Identifying insulin resistance is important to prevent development of glucose intolerance and the metabolic syndrome. Med J Aust 186: 269-270, author reply 271-262.
76. Kintscher U, Law RE (2005) PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 288: E287-E291.
77. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H (2002) Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs 16: 435-444.
78. KohjimaM, Sun Y, Chan L (2010) Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model. Endocrinology 151: 1532-1540.
79. Kuwano R (2007) Genetic risk factor of Alzheimer's disease. Rinsho Shinkeigaky 47: 908-911.
80. Landreth G (2006) PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp Neurol 199: 245-248.
81. Landreth G (2007) Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimers Res 4: 159-164.
82. Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5: 481-489.
83. Lee YH, Tharp WG, Maple RL, Nair S, Permana PA, Pratley RE (2008) Amyloid precursor protein expression is upregulated in adipocytes in obesity. Obesity (Silver Spring) 16: 1493-1500.
84. Lee YH, Martin JM, Maple RL, Tharp WG, Pratley RE (2009) Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. Neuroendocrinology 90: 383-390.
85. Lee IT, Chiu YF, Hwu CM, He CT, Chiang FT, Lin YC, Assimes T, Curb JD, Sheu WH (2012) Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc Diabetol 11: 43.
86. Li ZG, Zhang W, Sima AA (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56: 1817-1824.
87. Li J, Wang C, Zhang JH, Cai JM, Cao YP, Sun XJ (2010) Hydrogen-rich saline improves memory function in a rat model of amyloid-betainduced Alzheimer's disease by reduction of oxidative stress. Brain Res 1328: 152-161.
88. Liu SY, Zeng FF, Chen ZW, Wang CY, Zhao B, Li KS (2013) Vascular endothelial growth factor gene promoter polymorphisms and Alzheimer's disease risk: a meta-analysis. CNS Neurosci Ther 19: 469-476.
89. Lopez N, Tormo C, De Blas I, Llinares I, Alom J (2013) Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33: 823-829.
90. Lourenco MV, Ledo JH (2013) Targeting Alzheimer's pathology through PPARgamma signaling: modulation of microglial function. J Neurosci 33: 5083-5084.
91. Luchsinger JA, Mayeux R (2004) Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 6: 261-266.
92. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63: 1187-1192.
93. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29: 9078-9089.
94. Maccioni RB, Lavados M, Guillon M, Mujica C, Bosch R, Farias G, Fuentes P (2006) Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 27: 237-244.
95. Maitra SK, Rowland Payne CM (2004) The obesity syndrome and acanthosis nigricans. Acanthosis nigricans is a common cosmetic problem providing epidemiological clues to the obesity syndrome, the insulin-resistance syndrome, the thrifty metabolism, dyslipidaemia, hypertension and diabetes mellitus type II. J Cosmet Dermatol 3: 202-210.
96. Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptorgamma-mediated amyloid clearance and reversal of cognitive deficits in amurinemodel ofAlzheimer's disease. J Neurosci 32: 10117-10128.
97. Manolopoulos KN, Klotz LO, Korsten P, Bornstein SR, Barthel A (2010) Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry 15: 1046-1052.
98. Martin ED, Sanchez-Perez A, Trejo JL, Martin-Aldana JA, Cano Jaimez M, Pons S, Acosta Umanzor C, Menes L, White MF, Burks DJ (2012) IRS-2 Deficiency impairs NMDA receptor-dependent longterm potentiation. Cereb Cortex 22: 1717-1727.
99. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11: 721-736.
100. Medhi B, M. Chakrabarty (2013) Insulin resistance: an emerging link in Alzheimer's disease. Neurol Sci.
101. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis ofmild cognitive impairment and Alzheimer's disease: a metaanalysis of 51 studies. J Neurol Neurosurg Psychiatry 80: 966-975.
102. Mody N, Agouni A, McIlroy GD, Platt B, Delibegovic M (2011) Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 54: 2143-2151.
103. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31: 224-243.
104. MorabitoMV, Berman DE, Schneider RT, Zhang Y, Leibel RL, Small SA (2014) Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer's disease. Neurobiol Dis 65: 188-192.
105. Moreira PI (2012) Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 30(Suppl 2): S199-S215.
106. Moroz N, Tong M, Longato L, Xu H, de la Monte SM (2008) Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15: 29-44.
107. Mota SI, Ferreira IL, Pereira C, Oliveira CR, Rego AC (2012) Amyloidbeta peptide 1-42 causesmicrotubule deregulation through N-methyl-D-aspartate receptors in mature hippocampal cultures. Curr Alzheimers Res 9: 844-856.
108. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB (2008) Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimers Res 5: 438-447.
109. Nicolakakis N, Hamel E (2010) The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci. 2.
110. Nistico R, Cavallucci V, Piccinin S, Macri S, Pignatelli M, Mehdawy B, Blandini F, Laviola G, Lauro D, Mercuri NB, D'Amelio M (2012) Insulin receptor beta-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. Neuromol Med 14: 262-269.
111. Oyama N, Urasawa K, Sakai H, Fujii S, Kitabatake A (2005) Insulin resistance relates to acetylcholine-induced microvascular vasoconstriction in a patientwith vasospastic angina: potential implication of causalities between hyperinsulinemia and coronarymicrocirculation failure. Heart Vessel 20: 72-76.
112. Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J, Accili D (2011) Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 17: 961-967.
113. Park SA (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 7: 10-18.
114. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P (2012) Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29: 229-238.
115. Peng D, Pan X, Cui J, Ren Y, Zhang J (2013) Hyperphosphorylation of tau protein in hippocampus of central insulin-resistant rats is associated with cognitive impairment. Cell Physiol Biochem 32: 1417-1425.
116. Perry E (1988) Acetylcholine and Alzheimer's disease. Br J Psychiatry 152: 737-740.
117. Pinelli NR, Jaber LA, Brown MB, Herman WH (2010) Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 33: 1373-1375.
118. Pistrosch F, Passauer J, Herbrig K, Schwanebeck U, Gross P, Bornstein SR (2012) Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 44: 914-918.
119. Planel E, TatebayashiY, Miyasaka T, Liu L, Wang L, Herman M, YuWH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27: 13635-13648.
120. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, Riederer P, Hoyer S (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimerlike changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 19: 691-704.
121. Pomytkin IA (2012) H2O2 Signalling Pathway: A Possible Bridge between Insulin Receptor and Mitochondria. Curr Neuropharmacol 10: 311-320.
122. PrinceM, Cullen M, Mann A (1994) Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology 44: 97-104.
123. Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E, Murillo-Carretero MI, Perdomo G, Spires-Jones T, Cozar-Castellano I, Lechuga-Sancho AM, Garcia-Alloza M (2013a) Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 38: 2462-2475.
124. Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E, Murillo-Carretero MI, Perdomo G, Spires-Jones T, Cozar-Castellano I, Lechuga-Sancho AM, Garcia-Alloza M (2013b) Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology.
125. Ramos-Rodriguez JJ, Ortiz-Barajas O, Gamero-Carrasco C, de la Rosa PR, Infante-Garcia C, Zopeque-Garcia N, Lechuga-Sancho AM, Garcia-Alloza M (2014) Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. Psychoneuroendocrinology 48: 123-135.
126. Rasgon N, Jarvik L (2004) Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J Gerontol A Biol Sci Med Sci 59: 178-183, discussion 184-192.
127. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF (2010) Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci World J 10: 321-328.
128. Rasgon NL, Kenna HA, Wroolie TE, Kelley R, Silverman D, Brooks J, Williams KE, Powers BN, Hallmayer J, Reiss A (2011) Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 32: 1942-1948.
129. Reaven GM (2003) Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88: 2399-2403.
130. Reaven GM (2005) The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 25: 391-406.
131. Reaven GM (2011) Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich) 13: 238-243.
132. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70: 440-448.
133. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247-268.
134. Rusu P, Jansen A, Soba P, Kirsch J, Lower A, Merdes G, Kuan YH, Jung A, Beyreuther K, Kjaerulff O, Kins S (2007) Axonal accumulation of synaptic markers in APP transgenic Drosophila depends on the NPTY motif and is paralleled by defects in synaptic plasticity. Eur J Neurosci 25: 1079-1086.
135. Sabayan B, Foroughinia F, Mowla A, Borhanihaghighi A (2008) Role of insulin metabolism disturbances in the development of Alzheimer disease: mini review. Am J Alzheimers Dis Other Demen 23: 192-199.
136. Salkovic-PetrisicM, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 217-233.
137. Sarafidis PA, Bakris GL (2006) Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr 1: 334-342, quiz 343.
138. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, HenekaMT (2003)Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23: 9796-9804.
139. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, HenekaMT (2006) Nonsteroidal antiinflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103: 443-448.
140. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32: 1626-1633.
141. Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221: 555-563.
142. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23: 7084-7092.
143. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101: 3100-3105.
144. SchuhAF, RiederCM, Rizzi L, Chaves M, Roriz-CruzM (2011)Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. ISRN Neurol 2011: 306905.
145. Seo J, Giusti-Rodriguez P, Zhou Y, Rudenko A, Cho S, Ota KT, Park C, Patzke H, Madabhushi R, Pan L, Mungenast AE, Guan JS, Delalle I, Tsai LH (2014) Activity-dependent p25 generation regulates synaptic plasticity and Abeta-induced cognitive impairment. Cell 157: 486-498.
146. Shao J, Yamashita H, Qiao L, Friedman JE (2000) Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. J Endocrinol 167: 107-115.
147. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricularstreptozotocin injected rodents. Neurobiol Aging 33(430): e435-418.
148. Shpakov AO (2012) The functional state of biogenic amines-and acetylcholine-regulated signaling systems of the brain in diabetes mellitus. Tsitologiia 54: 459-468.
149. Sivanesan S, Tan A, Rajadas J (2013) Pathogenesis of Abeta oligomers in synaptic failure. Curr Alzheimers Res 10: 316-323.
150. Sommer G, Kralisch S, Lipfert J, Weise S, Krause K, Jessnitzer B, Lossner U, Bluher M, Stumvoll M, Fasshauer M (2009) Amyloid precursor protein expression is induced by tumor necrosis factor alpha in 3 T3-L1 adipocytes. J Cell Biochem 108: 1418-1422.
151. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I (2012a) Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 8: 1842-1844.
152. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I (2012b) Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes 61: 3126-3138.
153. Stein MS, Scherer SC, Ladd KS, Harrison LC (2011) A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J Alzheimers Dis 26: 477-484.
154. Sun X, Shao H, Yu D, Wang D (2010) Analysis of correlation between insulin resistance, blood lipids and Alzheimer's disease. Wei Sheng Yan Jiu 39: 573-575.
155. Sung KC, Lim S, Rosenson RS (2011) Hyperinsulinemia and homeostasis model assessment of insulin resistance as predictors of hypertension: a 5-year follow-up study of Korean sample. Am J Hypertens 24: 1041-1045.
156. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122: 1316-1338.
157. Tang W, Huang Q, Wang Y, Wang ZY, Yao YY (2014) Assessment of CSF Abeta as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. J Neurol Sci 345: 26-36.
158. Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306: 821-827.
159. Thomann PA, Kaiser E, Schonknecht P, Pantel J, Essig M, Schroder J (2009) Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci 34: 136-142.
160. To AW, Ribe EM, Chuang TT, Schroeder JE, Lovestone S (2011) The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS ONE 6: e16991.
161. TosunD, Joshi S, WeinerMW (2014) MultimodalMRI-based Imputation of the Abeta+in Early Mild Cognitive Impairment. Ann Clin Trans Neurol 1: 160-170.
162. Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, LotayN, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM (2010) A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis 22: 1241-1256.
163. Vagelatos NT, Eslick GD (2013) Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev.
164. Wang X, Yang Z, Xue B, Shi H (2011) Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology 152: 836-846.
165. Watanabe T, Yamagata N, Takasaki K, Sano K, Hayakawa K, Katsurabayashi S, Egashira N, Mishima K, Iwasaki K, Fujiwara M (2009) Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res 1249: 222-228.
166. Watson GS, Craft S (2003) The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17: 27-45.
167. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958.
168. Wevers A, Schroder H (1999) Nicotinic acetylcholine receptors in Alzheimer's disease. J Alzheimers Dis 1: 207-219.
169. Willette AA, Xu G, Johnson SC, Birdsill AC, Jonaitis EM, Sager MA, Hermann BP, La Rue A, Asthana S, Bendlin BB (2013) Insulin resistance, brain atrophy, and cognitive performance in late middleaged adults. Diabetes Care 36: 443-449.
170. Wlodarczyk A, Strojek K (2008) Glucose intolerance, insulin resistance and metabolic syndrome in patients with stable angina pectoris. Obesity predicts coronary atherosclerosis and dysglycemia. Pol Arch Med Wewn 118: 719-726.
171. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT (2012) PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 32: 17321-17331.
172. Yang Y, Ma D, Wang Y, Jiang T, Hu S, ZhangM, Yu X, Gong CX (2013) Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis 33: 329-338.
173. Yin QQ, Pei JJ, Xu S, Luo DZ, Dong SQ, Sun MH, You L, Sun ZJ, Liu XP (2013) Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS ONE 8: e59313.
174. Yoon SY, Park JS, Choi JE, Choi JM, LeeWJ, Kim SW, Kim DH (2010) Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SHSY5Y cells. Neurobiol Dis 40: 449-455.
175. Zempel H, Mandelkow EM (2012) Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 10: 64-72.
176. Zhang T, Pan BS, Zhao B, Zhang LM, Huang YL, Sun FY (2009) Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-secretase activation and betaamyloid generation in rat brains. Neuroscience 161: 1045-1056.
177. Zhang LJ, Xiao Y, Qi XL, Shan KR, Pei JJ, Kuang SX, Liu F, Guan ZZ (2010) Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (alpha4 and beta2 Subunits) in blood of elderly Chinese diagnosed as Alzheimer's disease. J Alzheimers Dis 19: 849-858.
178. Zhang Y, Zhou B, Deng B, Zhang F, Wu J, Wang Y, Le Y, Zhai Q (2013) Amyloid-beta induces hepatic insulin resistance in vivo via JAK2. Diabetes 62: 1159-1166.
179. Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792: 482-496.
180. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013: 316523.
181. Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, Hof P, Rocher A, Masur S, Haroutunian V, Pasinetti GM (2005) Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J 19: 2081-2082.
182. Zhong Y, Miao Y, Jia WP, Yan H, Wang BY, Jin J (2012) Hyperinsulinemia, insulin resistance and cognitive decline in older cohort. Biomed Environ Sci 25: 8-14.
183. Zolezzi JM, Silva-Alvarez C, Ordenes D, Godoy JA, Carvajal FJ, Santos MJ, Inestrosa NC (2013) Peroxisome proliferatoractivated receptor (PPAR) gamma and PPARalpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLoS ONE 8: e64019.